Roche's blockbuster breast cancer treatment Herceptin will face more competition after Pfizer's biosimilar won FDA approval March 11, according to Reuters.
The FDA has already approved biosimilar versions of Herceptin from Celltrion, Samsung Bioepis and Mylan.
Herceptin is one of Roche's top-selling drugs, bringing in about $6.93 billion in sales in 2018.
However, sales have been hit by increased biosimilar competition, according to the report.